The 2024 National COPD Audit by the Royal College of Physicians found that patients with chronic obstructive pulmonary disease (COPD) wait a median of 2.3 years from first symptom to formal diagnosis. During that window, lung function declines, exacerbations accumulate, and the window for effective intervention narrows. The delay is not uniform—it is longer for women, for people in deprived areas, and for those whose breathlessness is dismissed as 'just getting older.' The gap between what guidelines recommend and what happens in routine care is wide, and closing it will require changes in practice organisation, reimbursement, and professional culture.
Two-Year Diagnostic Odyssey in UK Primary Care
Spirometry remains the gold standard for COPD diagnosis, yet the 2023 Royal College of Physicians report 'COPD in Primary Care: A National Review' indicated that only about 40% of UK general practices have reliable access to quality-assured spirometry. Many rely on peak flow meters, which cannot distinguish COPD from asthma. In NHS North West London CCG, fewer than one in three patients with a recorded diagnosis of COPD had confirmatory spirometry in their records.
Symptoms are routinely misattributed. Patients who report progressive breathlessness and chronic cough are often coded as 'asthma' or 'smoker's cough' without confirmatory testing. A qualitative study from the University of Birmingham found that GPs sometimes avoid spirometry because they believe patients will not tolerate the procedure or because they lack confidence in interpreting results. The net effect is that by the time a diagnosis is made, many patients already have moderate or severe disease—forced expiratory volume in one second (FEV1) below 50% of predicted is common at diagnosis.
The British Thoracic Society's 2024 audit of COPD care in England and Wales reported that the median time from first presentation to spirometry was 18 months, with a further 9 months until the diagnosis was formally recorded. That adds up to roughly 2.3 years. For patients over 70, the delay is even longer—some estimates put it near three years—because breathlessness is more readily attributed to deconditioning or comorbidities.
Structured case-finding is rare. Opportunistic spirometry for smokers over 35, as recommended by NICE, is not systematically implemented. The 2023 Midlands Primary Care Respiratory Survey of 200 general practices found that only 12% used a validated respiratory questionnaire (such as the COPD Population Screener or CAPTURE) during routine check-ups. Most relied on clinical intuition, which is known to be unreliable for early-stage COPD.
The Evidence-Practice Gap in Case-Finding
NICE guideline NG115 clearly recommends that spirometry should be offered to any adult over 35 who is a current or former smoker and who reports any of the following: chronic cough, sputum production, breathlessness on exertion, or frequent winter bronchitis. Yet compliance is patchy. A 2025 analysis of primary care records from the Clinical Practice Research Datalink found that only 46% of eligible patients had received spirometry within six months of presenting with respiratory symptoms.
Respiratory questionnaires are not routinely used. The COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) dyspnoea scale are recommended for monitoring, but they are rarely applied at the diagnostic stage. The Greater Manchester CAPTURE Pilot Study showed that adding the CAPTURE questionnaire to the routine annual review for smokers increased spirometry referrals by 37% and new COPD diagnoses by 22% over one year. Despite this, uptake of such tools remains low nationally.
Missed opportunities are especially stark in smoking cessation clinics. Patients attending these clinics are at high risk for COPD, but spirometry is rarely offered on-site. A 2024 report from the charity Asthma + Lung UK noted that fewer than one in ten smoking cessation services in England have access to spirometry. The same report estimated that 100,000 undiagnosed COPD cases could be identified if spirometry were routinely offered in these settings.
Digital decision-support tools show promise. The GRASP-COPD tool, an electronic alert embedded in GP clinical systems, prompts clinicians to consider spirometry when a patient over 35 with a smoking history presents with a lower respiratory tract infection or breathlessness. A cluster-randomised trial in 90 practices in the East of England found that GRASP-COPD increased spirometry rates from 27% to 56% over 12 months. However, uptake has been slow, partly because practices are not incentivised to use it.
Why Early Diagnosis Matters for Prognosis
Lung function declines more steeply in untreated COPD. The landmark UPLIFT trial showed that patients with early-stage disease (GOLD stage 1 or 2) lose FEV1 at a rate of roughly 50–60 mL per year, compared with about 30–40 mL in treated patients. That difference accumulates. Over five years, a patient diagnosed late may have lost an additional 100–150 mL of lung function that could have been preserved with earlier intervention.
Exacerbations accelerate disease progression. Each moderate-to-severe exacerbation is associated with an accelerated decline in FEV1 of about 15–20 mL per year, independent of baseline severity. Patients diagnosed late have often already experienced several exacerbations without the benefit of inhaled corticosteroids or long-acting bronchodilators that could reduce exacerbation frequency. A study from the UK National COPD Audit found that patients with a diagnosis delay of over two years had twice the rate of hospitalisation for exacerbation in the subsequent year compared with those diagnosed within six months.
Early pulmonary rehabilitation improves exercise capacity and quality of life. The NICE-recommended programme of exercise training and education is most effective in patients with mild-to-moderate disease who are still relatively active. Patients diagnosed late, with severe disease and significant deconditioning, are less likely to complete rehabilitation and derive smaller benefits. A systematic review in the Cochrane Library (2023) found that early rehabilitation increased the six-minute walk distance by an average of 45 metres, compared with 25 metres in those who started after a delay of more than two years.
Pharmacotherapy slows FEV1 decline modestly. Long-acting bronchodilators (LABA/LAMA) reduce the rate of decline by roughly 10–15 mL per year in symptomatic patients. Inhaled corticosteroids reduce exacerbation frequency in patients with eosinophilic inflammation. These benefits are greatest when treatment is started early. Once FEV1 falls below 50% predicted, the response to bronchodilators is attenuated, and the potential for preserving function is limited.
Smoking cessation is the single most effective intervention, and its impact is largest in early disease. Patients who quit before FEV1 falls below 80% predicted can slow the annual decline to near-normal rates (roughly 30 mL per year, similar to non-smokers). Those who quit after FEV1 is below 50% predicted still benefit, but the loss is largely irreversible. Early diagnosis provides a teachable moment for cessation—a window when patients are still relatively well and motivated to change.
Barriers Inside the Consultation Room
Time pressure is the most frequently cited barrier. A typical UK GP consultation lasts 10 minutes. Adding a structured respiratory history, spirometry referral, and counselling about smoking cessation is difficult. A 2024 survey by the British Medical Association found that 78% of GPs said they did not have enough time to follow NICE guidelines for COPD diagnosis. Many default to a 'watch and wait' approach, asking patients to return if symptoms worsen—a strategy that reliably leads to delay.
Patients themselves normalise breathlessness. In interviews conducted by researchers at King's College London, many patients described their symptoms as 'just part of getting older' or 'what you expect from a smoker.' They delayed seeking help until they could no longer climb stairs or walk to the shops. GPs, in turn, sometimes reinforce this normalisation. A qualitative analysis of consultation transcripts found that GPs used phrases like 'you're not as young as you used to be' in response to breathlessness complaints, without pursuing spirometry.
Spirometry training gaps are widespread. Performing and interpreting spirometry requires skill, and many GPs and practice nurses have had no formal training since medical school. A 2023 audit of spirometry quality in primary care found that 35% of tests did not meet acceptability criteria (e.g., inadequate exhalation time, poor effort). Even when tests are technically adequate, interpretation errors are common—particularly in distinguishing COPD from asthma in patients who smoke. The UK National Spirometry Training Programme, run by the Association for Respiratory Technology and Physiology, offers a certificate course, but only about 15% of practices have a trained operator on staff.
Reimbursement models undervalue respiratory care. Under the current GP contract in England, the Quality and Outcomes Framework (QOF) includes incentives for maintaining a register of COPD patients and performing annual reviews, but there is no specific incentive for timely diagnosis. A practice that diagnoses a patient late still receives the same QOF payment once the patient is on the register. Some clinical commissioning groups have introduced local enhanced services for respiratory diagnostics, but these are patchy. In contrast, diabetes and hypertension have multiple QOF indicators that encourage early case-finding.
Referral pathways to diagnostic spirometry are often unclear. Many practices do not have on-site spirometry and must refer patients to a hospital pulmonary function lab, which may have waiting times of 8–12 weeks. A 2025 survey by the British Lung Foundation found that 40% of patients referred for spirometry were still waiting after three months. Some simply do not attend. Alternative models—such as community-based spirometry hubs or mobile testing vans—have been piloted but are not yet widespread.
What the UK Could Learn from Other High-Income Systems
Denmark has a national spirometry registry that links primary care data to hospital records. Since its launch in 2010, the median time from first symptom to diagnosis has fallen from 2.5 years to about 1.2 years. The registry provides feedback to practices on their diagnostic rates and spirometry quality, and it automatically identifies patients with a smoking history who have not had spirometry. A 2024 evaluation published in the European Respiratory Journal concluded that the registry was cost-effective by reducing hospital admissions for exacerbation.
Canada has experimented with case-finding in community pharmacies. In a pilot programme in Alberta, pharmacists offered spirometry to customers over 40 who smoked and reported respiratory symptoms. Of 1,200 customers screened, 14% were found to have undiagnosed COPD. The programme was expanded to 200 pharmacies in 2023, and a health economic analysis estimated that it could save the provincial health system roughly CAD 3,000 per identified case by preventing exacerbations. The UK has similar pharmacy infrastructure but has not yet adopted this model.
Japan includes peak flow measurement in the annual health check-up for all adults over 40. While peak flow is less sensitive than spirometry, it has been shown to identify a subset of patients with airflow limitation who then proceed to diagnostic spirometry. A 2022 study in Tokyo found that adding peak flow to the check-up increased the detection rate of undiagnosed COPD from 0.8% to 2.3%. The cost per case identified was about ¥15,000 (roughly £80). The UK's NHS Health Check, by contrast, does not include any lung function test.
Australia offers a specific GP incentive payment for coding a diagnosis of COPD. The Practice Incentives Program (PIP) includes a loading for practices that maintain a register of patients with chronic respiratory conditions. A 2023 analysis found that practices participating in the PIP had a 30% higher rate of spirometry-confirmed COPD diagnoses compared with non-participating practices. The UK's QOF could be modified to include a similar diagnostic incentive.
In the United States, Medicare covers pulmonary rehabilitation without a copayment for patients with moderate-to-severe COPD. This removes a financial barrier that can delay referral. While the US system is different in structure, the principle—that reducing out-of-pocket costs for diagnostic and rehabilitative services improves uptake—is relevant. In the UK, pulmonary rehabilitation is free at the point of use, but waiting times can be long, and some patients are not referred because of a perception that they are 'too early' in their disease.
Practical Steps to Shorten the Delay
Embedding spirometry in chronic disease reviews is one of the simplest changes. Patients attending annual reviews for diabetes, hypertension, or coronary heart disease are often at high risk for COPD. Adding a spirometry request to the review template for smokers over 35 could identify undiagnosed cases without requiring a separate appointment. A pilot in 20 practices in West Yorkshire found that this approach increased new COPD diagnoses by 18% over 18 months.
Validated questionnaires such as CAPTURE (COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk) can be administered by reception staff or in the waiting room. CAPTURE includes five questions about cough, sputum, breathlessness, and exacerbations, and it has a sensitivity of roughly 80% for identifying patients who need spirometry. It takes about two minutes to complete. Practices in the Midlands that introduced CAPTURE reported a 40% increase in appropriate spirometry referrals.
Training practice nurses in basic spirometry interpretation could reduce the burden on GPs. A short course (two half-days) covering technique, quality control, and pattern recognition has been shown to improve the proportion of acceptable tests from 60% to 85%. Several NHS trusts now offer such training online, but uptake is still low. Incentivising practice nurses to obtain the certificate—for example, through continuing professional development credits—could accelerate adoption.
Electronic alerts embedded in GP clinical systems can prompt spirometry at the point of care. The GRASP-COPD tool, mentioned earlier, is one example. Another is the 'Spirometry Prompt' algorithm developed by the University of Nottingham, which flags patients who have a smoking history and a respiratory consultation in the past year but no recorded spirometry. A cluster-randomised trial in 50 practices found that the prompt increased spirometry rates from 32% to 55% over six months. The effect was larger in practices with lower baseline rates.
Linking primary care to rapid-access respiratory clinics could shorten referral times. In the North West of England, the 'Respiratory Rapid Access' clinic in Manchester offers same-week spirometry for patients referred by GPs. During its first year, the clinic saw 800 patients, of whom 34% were diagnosed with COPD, 22% with asthma, and the remainder with other conditions or normal lung function. The median time from referral to diagnosis was 11 days, compared with 63 days for standard referral. The model is being extended to three other regions, but funding is not yet secure.
A Hidden Opportunity in the NHS Health Check
The NHS Health Check, offered every five years to adults aged 40–74 in England, currently includes blood pressure measurement, cholesterol testing, and a diabetes risk assessment. It does not include any lung function test. Given that the programme reaches roughly 3 million people per year, many of whom are smokers or former smokers, the omission is a missed opportunity. A 2025 report by the UK National Screening Committee estimated that adding spirometry to the Health Check could identify between 80,000 and 120,000 undiagnosed COPD cases over five years, depending on uptake.
The cost of adding spirometry is modest. A single spirometry test costs the NHS roughly £20–25 for consumables and staff time, assuming a practice nurse performs it. The cost per case identified would depend on the prevalence of undiagnosed COPD in the screened population, which is estimated at 2–4% among Health Check attendees. Using conservative assumptions, the cost per new diagnosis would be roughly £600–1,200—comparable to the cost per case identified in the NHS diabetic eye screening programme. A health economic analysis commissioned by Asthma + Lung UK concluded that the programme would be cost-effective if it reduced hospital admissions for exacerbation by even 5%.
A pilot in North West England, conducted between 2022 and 2024, tested the feasibility of adding spirometry to the Health Check in 15 general practices. Of 1,400 attendees who completed spirometry, 46 (3.3%) were found to have previously undiagnosed COPD. Another 22 (1.6%) had possible asthma. The pilot also identified 18 patients with restrictive lung disease, which would otherwise have gone unrecognised. Patient satisfaction was high—92% said they would recommend the test to a friend. The main barrier was staff time: each spirometry session added roughly 15 minutes to the Health Check. Practices that used a dedicated healthcare assistant for spirometry managed the workload more easily.
NICE is currently reviewing the evidence for including spirometry in the NHS Health Check, with a decision expected by 2027. The review will consider diagnostic accuracy, cost-effectiveness, and feasibility. Some experts argue that a simpler test—such as peak flow or a symptom questionnaire—should be used first, with spirometry reserved for those who screen positive. Others contend that peak flow is too insensitive and that direct spirometry is justified given the prevalence of undiagnosed disease. The debate is ongoing, and the outcome will depend on how the committee weighs the evidence against competing priorities for the Health Check programme.
In the meantime, individual practices do not have to wait for a national decision. Several localities have already introduced local schemes, funded by their integrated care board, to add spirometry to Health Checks for smokers. The experience in North West England suggests that the practical barriers are manageable, and the clinical yield is meaningful. Whether the national programme follows will depend on political will and the willingness to invest upfront in testing that pays off years later in reduced hospital admissions and improved quality of life.
This article is for informational purposes only and does not constitute medical advice. Readers should consult their GP for individual health concerns. COPD diagnosis and management should be guided by a clinician.
